HealthlineBlood Thinner May Slow Cognitive Decline in Alzheimer’s Patients with AFib

🧠 Mental Health / Behavioral Sensitivity

Patients with Alzheimer’s disease and atrial fibrillation face elevated stroke risk and ongoing cerebrovascular injury. In a Swedish registry analysis of more than 7,300 patients, NOAC therapy was associated with slower cognitive decline and fewer adverse outcomes than warfarin or no anticoagulation.

Clinical Considerations

• NOAC users demonstrated slower MMSE decline than both warfarin users and patients receiving no anticoagulation.
• Stroke, mortality, and fracture risks were lower among NOAC users without increased major bleeding.
• Warfarin reduced stroke and mortality risk but showed higher major bleeding rates than NOAC therapy.
• Findings derive from a retrospective observational cohort and remain vulnerable to residual confounding.

Practice Applications

• Recognize atrial fibrillation as a potential contributor to ongoing cerebrovascular injury in dementia.
• Interpret cognitive findings as observational associations rather than evidence of disease modification.
• Consider adherence challenges when evaluating anticoagulation strategies in cognitively impaired patients.
• Monitor emerging evidence examining cognition-related outcomes in anticoagulated dementia populations.